{"nctId":"NCT01369355","briefTitle":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)","startDateStruct":{"date":"2011-09-13","type":"ACTUAL"},"conditions":["Crohn's Disease","Colitis","IBD","Inflammatory Bowel Disease"],"count":1282,"armGroups":[{"label":"001","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo SC"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Drug: Ustekinumab 90 mg SC q12w"]},{"label":"003","type":"EXPERIMENTAL","interventionNames":["Drug: Ustekinumab 90 mg SC q8w"]},{"label":"004","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo IV","Drug: Ustekinumab 90 mg SC q8w"]},{"label":"005","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo SC","Drug: Ustekinumab 130 mg IV","Drug: Ustekinumab 90 mg SC q12w"]},{"label":"006","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo SC"]}],"interventions":[{"name":"Placebo SC","otherNames":[]},{"name":"Placebo IV","otherNames":[]},{"name":"Ustekinumab 90 mg SC q8w","otherNames":[]},{"name":"Ustekinumab 130 mg IV","otherNames":[]},{"name":"Ustekinumab 90 mg SC q12w","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who received study agent at the start of study CNTO1275CRD3001 or CNTO1275CRD3002 and completed the Week 8 visit. Exclusion Criteria:\n* Patients who underwent a Crohn's disease-related surgery since the start of induction study CNTO1275CRD3001 or CNTO1275CRD3002\n* Patients who started a protocol prohibited medication since the start of studies CNTO1275CRD3001 and CNTO1275CRD3002\n* Patients with protocol-specified changes to their concomitant medications due to Crohn's disease (due to lack of efficacy) since the start of studies CNTO1275CRD3001 and CNTO1275CRD3002","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Clinical Remission at Week 44","description":"Clinical remission at Week 44 was defined as a Crohn's Disease Activity Index (CDAI) score of \\<150 points (in general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities). CDAI was assessed by collecting information on 8 different Crohn's disease-related variables (extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being). A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinical Response at Week 44","description":"Clinical response at Week 44 was defined as a reduction from baseline in the Crohn's Disease Activity Index (CDAI) score of greater than or equal (\\>=) 100 points. Participants with a baseline CDAI score of \\> = 220 to less than or equal (\\< =) 248 were considered to be in clinical response if a CDAI score of less than (\\<) 150 was attained. A CDAI score of less than 150 indicates clinical remission. A decrease in CDAI score over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Clinical Remission at Week 44 Among Participants in Clinical Remission to Ustekinumab at Week 0 of Maintenance Study","description":"Clinical remission at week 44 was defined as a CDAI score of \\< 150 points among participants in clinical remission to ustekinumab at week 0 of maintenance study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Corticosteroid-free Remission at Week 44","description":"Corticosteroid-free remission at Week 44 was defined as a CDAI score of \\<150 points without receiving corticosteroids at Week 44.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Clinical Remission at Week 44 in the Subset of Participants Who Were Refractory or Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy","description":"Clinical remission at Week 44 was defined as a CDAI score of \\<150 points in the subset of participants who were refractory or Intolerant to tumor necrosis factor antagonist therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":133},"commonTop":["Nasopharyngitis","Crohn's Disease","Arthralgia","Abdominal Pain","Upper Respiratory Tract Infection"]}}}